Followers | 10 |
Posts | 1578 |
Boards Moderated | 0 |
Alias Born | 10/15/2014 |
Friday, May 25, 2018 3:01:44 PM
So really, what we have now is a one drug trial of 161 TIVO participants with data readout triggered at reaching 94 PFS events (the 255 PFS events required including sorafenib participants, minus the 161 sorafenib participants).
The mPFS will be determined based on where the 80th patient falls (the 50% mark), but we don’t get the data until we hit the 94th PFS event. So, for all we know, the 80th patient has already had a PFS event but we are waiting out the 94th PFS event for data.
The only thing we can say with certainty is that at least 93 participants have not had a PFS event yet. So, at a minimum 93 of 161 participants (57.7%) remain disease free for at least 8 months (assuming worst case scenario of dosing in August 2017 and a two month data lag). That allows us to predict with absolute certainty that the trial’s goal (mPFS of six months) has been met and exceeded by two months.
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM